Comparison of the in vivo reconstitution capacity of UCB-derived CD34+, CD34+BB9+, and CD34+BB9− subpopulations in the NOD/SCID mouse model
| No. of injected cells . | Proportion of engrafted mice* . |
|---|---|
| CD34+ | |
| 1 × 103 | 0/5 |
| 3 × 103 | 1/7 |
| 10 × 103 | 5/6 |
| 30 × 103 | 5/5 |
| CD34+BB9+ | |
| 1 × 103 | 5/12 |
| 3 × 103 | 2/5 |
| 5 × 103 | 5/6 |
| 10 × 103 | 12/13 |
| 20 × 103 | 5/5 |
| 30 × 103 | 5/5 |
| CD34+BB9− | |
| 25 × 103 | 0/4 |
| 50 × 103 | 0/2 |
| No. of injected cells . | Proportion of engrafted mice* . |
|---|---|
| CD34+ | |
| 1 × 103 | 0/5 |
| 3 × 103 | 1/7 |
| 10 × 103 | 5/6 |
| 30 × 103 | 5/5 |
| CD34+BB9+ | |
| 1 × 103 | 5/12 |
| 3 × 103 | 2/5 |
| 5 × 103 | 5/6 |
| 10 × 103 | 12/13 |
| 20 × 103 | 5/5 |
| 30 × 103 | 5/5 |
| CD34+BB9− | |
| 25 × 103 | 0/4 |
| 50 × 103 | 0/2 |
Engraftment is based on flow cytometric analysis of bone marrow cells from recipient mice harvested at 10 weeks after transplantation and is defined as more than 1% human CD45+ cells.